Compare · RVMD vs SRRK
RVMD vs SRRK
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Scholar Rock Holding Corporation (SRRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and SRRK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.73B, about 5.8x SRRK ($6.80B).
- Over the past year, RVMD is up 386.9% and SRRK is up 47.1% - RVMD leads by 339.9 points.
- RVMD has been more active in the news (15 items in the past 4 weeks vs 8 for SRRK).
- RVMD has more recent analyst coverage (25 ratings vs 19 for SRRK).
- Company
- Revolution Medicines Inc.
- Scholar Rock Holding Corporation
- Price
- $186.83-2.29%
- $56.75-2.09%
- Market cap
- $39.73B
- $6.80B
- 1M return
- +24.87%
- +24.44%
- 1Y return
- +386.92%
- +47.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 15
- 8
- Recent ratings
- 25
- 19
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)
Latest SRRK
- Director Burow Kristina sold $164,064 worth of shares (3,053 units at $53.74), decreasing direct ownership by 3% to 114,657 units (SEC Form 4) (tax liability)
- Director Flier Jeffrey S. sold $164,490 worth of shares (3,053 units at $53.88), decreasing direct ownership by 10% to 27,856 units (SEC Form 4) to cover withholding tax
- Director Gilman Michael sold $137,058 worth of shares (2,544 units at $53.87), decreasing direct ownership by 4% to 59,511 units (SEC Form 4) (tax withholding)
- Director Reed Joshua sold $164,067 worth of shares (3,053 units at $53.74), decreasing direct ownership by 14% to 19,518 units (SEC Form 4) to cover taxes
- Director Peng Katie sold $293,405 worth of shares (5,446 units at $53.88), decreasing direct ownership by 14% to 34,301 units (SEC Form 4) (withholding tax)
- SEC Form 144 filed by Scholar Rock Holding Corporation
- SEC Form 144 filed by Scholar Rock Holding Corporation
- Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)